“The moments that matter most for a patient’s health often happen at home, not in the clinic.” That line came from Jeffrey Ferranti, chief digital officer of Duke Health, and it explains why a hospital system is now an investor in a startup.
Cadence, a remote patient monitoring company, raised $100 million in a Series C round, TechTarget reported on 24 June 2026. Spark Capital led. Hospital systems, including Memorial Hermann and Duke Health, also put money in. Health systems are usually the customers of companies like this one. Here they hold a stake.
What the platform does
Cadence builds software and connected devices for chronic care. It covers hypertension, type 2 diabetes, heart failure and chronic obstructive pulmonary disease. Devices at the patient’s home collect vital sign readings and pass them to a clinical team. The company also supplies a physician-led team so health systems can stay in touch with patients between appointments.
AI sits inside that loop. Cadence says its AI agents watch patient vitals, support medication adjustments and give personalized lifestyle coaching. They are also trained to flag risk between clinic visits.
Chris Altchek, the company’s founder and CEO, described the thinking behind it: “We built Cadence to solve the clinical labor constraint at the heart of the chronic disease crisis.” In his account, the AI automates care under close supervision, guided by the company’s medical group and governed by health system clinical protocols.
Where the money goes
Cadence said it will use the funds to expand its technology and services across health systems, advance its AI agents and grow value-based care models. It also announced new affiliations with Duke Health and Texas Health Resources. The company says it works with over 20 health systems, Providence among them, and treats more than 100,000 patients.
Ferranti put the Duke side this way: “With Cadence, we stay connected to patients with chronic conditions around the clock, monitoring their health continuously so we can intervene early and keep them healthy.”
Patient trust is not settled
The raise lands while at-home health devices are gaining ground. A 2025 survey cited by TechTarget found more than half of respondents agreed remote monitoring with at-home devices can match in-clinic care for certain conditions. A third said they worry about the safety of AI-powered medical devices.
That split is the market Cadence is selling into. Patients should raise any change to their care routine with their own doctor first.
